1295 logo

Synbio Tech TPEX:1295 Stock Report

Last Price

NT$116.00

Market Cap

NT$4.0b

7D

11.5%

1Y

76.6%

Updated

21 Jun, 2025

Data

Company Financials

Synbio Tech (1295) Stock Overview

Engages in the research and manufacture of probiotics. More details

1295 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends1/6

1295 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Synbio Tech Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Synbio Tech
Historical stock prices
Current Share PriceNT$116.00
52 Week HighNT$120.00
52 Week LowNT$58.50
Beta0
1 Month Change73.13%
3 Month Change54.67%
1 Year Change76.60%
3 Year Changen/a
5 Year Changen/a
Change since IPO51.69%

Recent News & Updates

Recent updates

Shareholder Returns

1295TW BiotechsTW Market
7D11.5%-2.4%-0.2%
1Y76.6%-11.4%-6.0%

Return vs Industry: 1295 exceeded the TW Biotechs industry which returned -11.4% over the past year.

Return vs Market: 1295 exceeded the TW Market which returned -6% over the past year.

Price Volatility

Is 1295's price volatile compared to industry and market?
1295 volatility
1295 Average Weekly Movement10.8%
Biotechs Industry Average Movement8.3%
Market Average Movement7.4%
10% most volatile stocks in TW Market10.1%
10% least volatile stocks in TW Market4.9%

Stable Share Price: 1295's share price has been volatile over the past 3 months compared to the TW market.

Volatility Over Time: 1295's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

FoundedEmployeesCEOWebsite
1989n/an/awww.synbiotech.com

Synbio Tech Inc. engages in the research and manufacture of probiotics. The company provides SynForU-MemoryUp, a solution for brain health; Lactobacillus plantarum TWK10 for exercise performance; ABKEFIR to improve digestive and promote human health; SynForU-ImmuUp for immune system; SynForU-GastroKeep, a stomach care probiotic; SynForU-HepaAid, a liver care probiotic; SynForU-HerCare, which inhibit the growth of fungal and bacterial pathogens, and maintain the vaginal microbiome in proper balance; SynForU-Remain, a kidney care solution; and multi strain probiotics. Its single probiotics strain includes bacillus coagulans, bifidobacterium animalis subsp.

Synbio Tech Inc. Fundamentals Summary

How do Synbio Tech's earnings and revenue compare to its market cap?
1295 fundamental statistics
Market capNT$4.00b
Earnings (TTM)NT$0
Revenue (TTM)n/a
n/a
P/E Ratio
n/a
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1295 income statement (TTM)
RevenueNT$0
Cost of RevenueNT$0
Gross ProfitNT$0
Other ExpensesNT$0
EarningsNT$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did 1295 perform over the long term?

See historical performance and comparison

Dividends

4.3%
Current Dividend Yield
n/a
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/21 22:39
End of Day Share Price 2025/06/20 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Synbio Tech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.